Aptar Pharma, a global leader in drug delivery and active material science solutions and services, announces its acquisition of the clinical trial materials manufacturing capabilities of Mod3 Pharma (formerly Enteris Biopharma) from SWK Holdings. This strategic move strengthens Aptar’s support for early-stage drug development by offering formulation, fill and finish services for Phase 1 and 2 clinical trials and enhances adoption of its proprietary devices in early-stage clinical programs. This acquisition builds on a successful collaboration between Aptar Pharma and Mod3 Pharma, particularly in serving Aptar Pharma customers with Phase 1 and Phase 2 cGMP fill and finish services for orally inhaled nasal drug products (OINDPs), filling a largely unmet need in the market.
Read the full article: Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition //
Source: https://www.businesswire.com/news/home/20250715970521/en/Aptar-Pharma-Bolsters-Clinical-Trial-Capabilities-with-Strategic-Materials-Manufacturing-Acquisition